



**Stronger together:
BioVendor Group
enters a new era**

Focused on innovation.
Committed to you.

Bringing expertise together as one

Three global divisions, a unified brand identity, closer integration of research, operations, and customer support – the new model brings faster innovation, greater reliability, and stronger partnerships for laboratories and patients.

Driving innovation, strengthening support



Michal Beránek



Martin Zeppetzauer



Béatrice de Borman

Immunodiagnostics

Molecular Diagnostics

Radio-immunodiagnostics

More value for your business, more trust for your customers



Faster innovation



Reliable diagnostics
(IVDR included)



Stronger collaboration



One trusted partner

 BioVendor LLC

2004

 TestLine

2012

1992

 BioVendor LM

1995

 BioVendor R&D

2011

 BioVendor Slovakia

One brand, one identity



Under this transformation, BioVendor Group becomes the unifying brand across all markets and communication channels.

For regulatory reasons, established company names such as TestLine, ViennaLab and DiaSource remain visible on product packaging as legal manufacturers.



Strong vision for better diagnostics

At the core of this transformation lies a renewed vision:

To be the trusted innovator in specialty clinical diagnostics, transforming patient needs into advanced solutions for better care and more effective healthcare systems.

This vision expresses our ambition and enduring commitment to science, partnership, and better care through diagnostics. With this transformation, we are ready to advance diagnostics with you, our partners.



2016



2021



2026

2017




2025



About BioVendor Group

We are an international group of biotechnology companies with expertise in immunodiagnostics, molecular diagnostics, and radio-immunodiagnostics. Founded in 1992 in the Czech Republic, we have grown from a local company into a global innovator with in-house research, development, and production of *in-vitro* diagnostic (IVD) products, supported by an international distribution network.

Our strategy is anchored by three key projects – CLIA, MBA, and NGS – focusing our innovation and delivery across next-generation sequencing, chemiluminescent immunoassays, and Microblot-Array. By combining scientific excellence, strong innovation capacity, and a presence in more than 100 markets worldwide, we deliver solutions that advance laboratory practice and patient care, making us one of the key players in clinical diagnostics.



**We are ready
to stand by your side**



Laurent Collignon
Chief Commercial Officer
laurent.collignon@biowendor.com
+33 6 08 65 34 76



Michal Šteffl
Head of International Sales
steffl@testlinecd.com
+420 601 376 271